The dispensing and drug accountability responsibilities of investigational agents are critical to the research process. The number and complexity of investigator-initiated studies was the driving force behind the creation of the Investigational Drug Service (IDS) by the Department of Pharmacy and Clinical Research Services. IDS provides expert pharmaceutical consultation for each pilot, phase I and II investigator-initiated research study, utilizing pharmaceutical products. Barbara Todaro, PharmD, is the IDS Director;in 2006, she consulted on thirty-one investigator-initiated studies prior to SRC submission. Alison Meagher, PharmD, is the assistant director of the Phase I committee. Under Dr. Meagher's direction the reporting processes for adverse events and monitoring of phase I patients has been streamlined. At the time of this submission, IDS was responsible for 72 inventory items for 43 separate investigatorinitiated studies. A member of IDS attends all study initiation meetings and in 2006, there were 15 implementation meetings for investigator-initiated research studies. IDS works closely with RPCI investigators to ensure appropriate drug and dosage forms are available for investigational drugs requiring complex preparation procedures. Examples include studies involving intravenous calcitriol, bupropion and tetrathiomolybdate, which are supported by multiple grants in several CCSG programs. 3.3 FTEs are required to support all relevant clinical trials that are under the RPCI protocol-specific research support. This application seeks 0.3FTE support for this function, with additional support to be provided by institutional sources as well as study sponsors (NIH/CTEP, industry, foundations). $33,281 in CCSG support is requested.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390
Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5
Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:
Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568
Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Ho, Christine M; McCarthy, Philip L; Wallace, Paul K et al. (2017) Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv 1:1056-1066

Showing the most recent 10 out of 1391 publications